Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul 14:15:e13.
doi: 10.15420/usc.2021.05. eCollection 2021.

Door-to-balloon Time for ST-elevation MI in the Coronavirus Disease 2019 Era

Haytham Mously  1 , Nischay Shah  1 , Zachary Zuzek  1 , Ibrahim Alshaghdali  1 , Adham Karim  1 , Rahul Jaswaney  1 , Steven J Filby  1 , Daniel I Simon  1 , Mehdi H Shishehbor  1 , Farshad Forouzandeh  1
Affiliations
Review

Door-to-balloon Time for ST-elevation MI in the Coronavirus Disease 2019 Era

Haytham Mously et al. US Cardiol. .

Abstract

In patients presenting with ST-elevation MI, prompt primary coronary intervention is the preferred treatment modality. Several studies have described improved outcomes in patients with door-to-balloon (D2B) and symptom onset-to-balloon (OTB) times of less than 2 hours, but the specific implications of the coronavirus disease 2019 (COVID-19) pandemic on D2B and OTB times are not well-known. This review aims to evaluate the impact of COVID-19 on D2B time and elucidate both the factors that delay D2B time and strategies to improve D2B time in the contemporary era. The search was directed to identify articles discussing the significance of D2B times before and during COVID-19, from the initialization of the database to December 1, 2020. The majority of studies found that onset-of-symptom to hospital arrival time increased in the COVID-19 era, whereas D2B time and mortality were unchanged in some studies and increased in others.

Keywords: Percutaneous coronary intervention; ST-elevation myocardial infarction; coronavirus disease 2019; door-to-balloon time; healthcare outcome.

PubMed Disclaimer

Conflict of interest statement

Disclosure: FF is a section editor on the US Cardiology Review editorial board; this did not influence peer review. All other authors have no conflicts of interest to declare.

Figures

Figure 1:
Figure 1:. Factors Contributing to Delay in Door-to-balloon Time in the Coronavirus Disease 2019 Era
Figure 2:
Figure 2:. Strategies to Achieve Lower Door-to-balloon and Symptom Onset-to-balloon Time in the Coronavirus Disease 2019 Era
See this image and copyright information in PMC

References

    1. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003;361:13–20. doi: 10.1016/s0140-6736(03)12113-7. - DOI - PubMed
    1. De Luca G, Suryapranata H, Ottervanger JP, Antman EM. Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction. Circulation. 2004;109:1223–5. doi: 10.1161/01.cir.0000121424.76486.20. - DOI - PubMed
    1. Pati D, Lorusso LN. How to write a systematic review of the literature. HERD. 2018;11:15–30. doi: 10.1177/1937586717747384. - DOI - PubMed
    1. Berger PB, Ellis SG, Holmes DR et al. Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction. Circulation. 1999;100:14–20. doi: 10.1161/01.cir.100.1.14. - DOI - PubMed
    1. Cannon CP, Gibson CM, Lambrew CT et al. Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. JAMA. 2000;283:2941–7. doi: 10.1001/jama.283.22.2941. - DOI - PubMed

LinkOut - more resources